Tandem Diabetes Care Dirección

Dirección controles de criterios 3/4

El CEO de Tandem Diabetes Care's es John Sheridan , nombrado en Apr 2013, tiene una permanencia de 4.83 años. compensación anual total es $4.65M, compuesta por 15.3% salario y 84.7% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.046% de las acciones de la empresa, por valor de €889.88K. La antigüedad media del equipo directivo y de la junta directiva es de 2.6 años y 4.3 años, respectivamente.

Información clave

John Sheridan

Chief Executive Officer (CEO)

US$4.7m

Compensación total

Porcentaje del salario del CEO	15.3%
Permanencia del CEO	11.1yrs
Participación del CEO	0.05%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	4.4yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de John Sheridan en comparación con los beneficios de Tandem Diabetes Care?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	-US$141m
Dec 31 2023	US$5m	US$711k	-US$223m
Sep 30 2023	n/a	n/a	-US$208m
Jun 30 2023	n/a	n/a	-US$224m
Mar 31 2023	n/a	n/a	-US$204m
Dec 31 2022	US$6m	US$711k	-US$95m
Sep 30 2022	n/a	n/a	-US$68m
Jun 30 2022	n/a	n/a	-US$13m
Mar 31 2022	n/a	n/a	US$6m
Dec 31 2021	US$6m	US$690k	US$16m
Sep 30 2021	n/a	n/a	US$22m
Jun 30 2021	n/a	n/a	US$7m
Mar 31 2021	n/a	n/a	-US$25m
Dec 31 2020	US$4m	US$600k	-US$34m
Sep 30 2020	n/a	n/a	-US$49m
Jun 30 2020	n/a	n/a	-US$42m
Mar 31 2020	n/a	n/a	-US$17m
Dec 31 2019	US$11m	US$500k	-US$25m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$55m
Mar 31 2019	n/a	n/a	-US$113m
Dec 31 2018	US$2m	US$386k	-US$123m
Sep 30 2018	n/a	n/a	-US$138m
Jun 30 2018	n/a	n/a	-US$119m
Mar 31 2018	n/a	n/a	-US$82m
Dec 31 2017	US$596k	US$375k	-US$73m

Compensación vs. Mercado: La compensación total de John($USD4.65M) está por encima de la media de empresas de tamaño similar en el mercado German ($USD1.62M).

Compensación vs. Ingresos: La compensación de John ha sido consistente con los resultados de la empresa en el último año.

CEO

John Sheridan (68 yo)

11.1yrs

Permanencia

US$4,651,603

Compensación

Mr. John F. Sheridan has been President and Chief Executive Officer at Tandem Diabetes Care, Inc., since March 01, 2019 and served as its Chief Operating Officer and Executive Vice President since April 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
John Sheridan	President	11.1yrs	US$4.65m	0.046% $ 1.2m
Leigh Vosseller	Executive VP	6.3yrs	US$1.25m	0.038% $ 1.0m
Susan Morrison	Executive VP & Chief Administrative Officer	10.7yrs	US$1.25m	0.024% $ 641.8k
David Berger	Transitional Advisor	less than a year	US$1.25m	0.011% $ 289.9k
Brian Hansen	Executive Officer	8.3yrs	US$1.27m	0.021% $ 552.0k
Elizabeth Gasser	Executive Vice President and Chief Strategy & Product Officer	2.9yrs	US$1.25m	0.010% $ 266.9k
Mark Novara	Executive VP & Chief Commercial Officer	less than a year	US$2.72m	sin datos
Rick Carpenter	Chief Technical Officer	2.5yrs	sin datos	0.0095% $ 253.4k
Shannon Hansen	Executive VP	2.3yrs	sin datos	0.0085% $ 229.0k
Tom Fox	Chief Human Resources Officer	6.8yrs	sin datos	sin datos
Jordan Pinsker	Chief Medical Officer	less than a year	sin datos	sin datos
Libba Sapitsky	Senior Vice President of Customer Care	2.5yrs	sin datos	sin datos

2.7yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TD5A se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
John Sheridan	President	4.9yrs	US$4.65m	0.046% $ 1.2m
Rebecca Robertson	Independent Chairwoman of the Board	5.3yrs	US$222.78k	0.0077% $ 206.2k
Kim Blickenstaff	Director	16.7yrs	US$198.78k	0.34% $ 9.1m
Christopher Twomey	Independent Director	10.8yrs	US$200.95k	0.030% $ 811.6k
Dick Allen	Independent Director	16.8yrs	US$214.67k	0.074% $ 2.0m
Peyton Howell	Independent Director	3.8yrs	US$190.28k	0.019% $ 509.0k
Rajwant Sodhi	Independent Director	3.3yrs	US$189.25k	0.010% $ 278.4k
Kathleen McGroddy-Goetz	Independent Director	3.9yrs	US$189.25k	0.014% $ 375.2k
Myoungil Cha	Independent Director	1.9yrs	US$176.55k	0.0027% $ 72.7k
Joao Paulo Malagueira	Independent Director	1.9yrs	US$177.55k	0.0027% $ 72.7k

4.4yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de TD5A se considera experimentada (4.3 años de antigüedad promedio).

Tandem Diabetes Care Dirección

Dirección controles de criterios 3/4

Información clave

Actualizaciones recientes de la dirección

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

Independent Director recently bought €274k worth of stock

Executive VP recently bought €91k worth of stock

High number of new directors

High number of new directors

Recent updates

First quarter 2024 earnings released: US$0.65 loss per share (vs US$1.92 loss in 1Q 2023)

Tandem Diabetes Care, Inc. to Report Q1, 2024 Results on May 02, 2024

Now 23% undervalued

Full year 2023 earnings released: US$3.43 loss per share (vs US$1.48 loss in FY 2022)

Tandem Diabetes Care Launches Tandem Mobi, the World’s Smallest, Durable Automated Insulin Delivery System

Tandem Diabetes Care, Inc. to Report Q4, 2023 Results on Feb 21, 2024

Tandem Diabetes Care, Inc. Announces Full U.S. Launch of Tandem Source, a New Diabetes Management Platform for Customers and Healthcare Providers

Tandem Diabetes Care, Inc. Launches T:Slim X2 Insulin Pump Software with Dexcom G7 CGM Integration in U.S

Third quarter 2023 earnings released: US$0.51 loss per share (vs US$0.76 loss in 3Q 2022)

Tandem Diabetes Care, Inc. Appoints Mark Novara as Executive Vice President and Chief Commercial Officer, Effective November 13, 2023

Tandem Diabetes Care, Inc. to Report Q3, 2023 Results on Nov 01, 2023

Holzer & Holzer, LLC Files Class Action Lawsuit Filed on Behalf of Tandem Diabetes Care, Inc

Now 21% undervalued

Tandem Diabetes Care, Inc. Announces the Resignation of Brian B. Hansen as Executive Vice President and Chief Commercial Officer, Effective December 31, 2023

New major risk - Share price stability

Now 32% undervalued after recent price drop

Second quarter 2023 earnings released: US$0.55 loss per share (vs US$0.23 loss in 2Q 2022)

Tandem Diabetes Care, Inc. Receives U.S. FDA Clearance

Tandem Diabetes Care, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently bought €274k worth of stock

Executive VP recently bought €91k worth of stock

First quarter 2023 earnings released: US$1.92 loss per share (vs US$0.23 loss in 1Q 2022)

Full year 2022 earnings released: US$1.48 loss per share (vs US$0.25 profit in FY 2021)

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) completed the acquisition of AMF Medical SA .

Tandem Diabetes Care, Inc. to Report Q4, 2022 Results on Feb 22, 2023

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) entered into a definitive agreement to acquire AMF Medical SA for CHF million.

High number of new directors

Tandem Diabetes Care, Inc. Study Demonstrates Improvements of All Clinical Endpoints in Adults with Type 2 Diabetes Using Control-IQ Technology

Now 31% undervalued after recent price drop

Third quarter 2022 earnings released: US$0.76 loss per share (vs US$0.092 profit in 3Q 2021)

Tandem Diabetes Care, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Tandem Diabetes Care Achieves Milestone of 1 Million Insulin Boluses Delivered Using Its t:Connect Mobile App

Second quarter 2022 earnings released: US$0.23 loss per share (vs US$0.064 profit in 2Q 2021)

Tandem Diabetes Care, Inc. Updates Sales Guidance for the Full Year of 2022

High number of new directors

Tandem Diabetes Care, Inc. (NasdaqGM:TNDM) acquired Capillary Biomedical, Inc.

Tandem Diabetes Care, Inc. to Report Q2, 2022 Results on Aug 03, 2022

High number of new directors

Tandem Diabetes Care Reports the Appointments of Myoung Cha and Joao Malagueira as Independent Members of Its Board of Directors, as of June 15, 2022

Tandem Diabetes Care, Inc. Appoints Myoung Cha and Joao Malagueira as Independent Members of its Board of Directors

Executive VP & COO recently sold €187k worth of stock

Executive VP recently bought €177k worth of stock

Now 21% undervalued after recent price drop

Tandem Diabetes Care, Inc. Revises Financial Guidance for the Full Year Ending December 31, 2022

Tandem Diabetes Care, Inc., Annual General Meeting, May 25, 2022

Tandem Diabetes Care, Inc. to Report Q1, 2022 Results on May 04, 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Tandem Diabetes Care, Inc. Appoints David B. Berger as Executive Vice President, Chief Operating Officer and Assistant Secretary

Now 21% undervalued after recent price drop

Tandem Diabetes Care, Inc. Announces FDA Clearance for the t:slim X2 Insulin Pump to Bolus Using the t:connect Mobile App

Third quarter 2021 earnings released: EPS US$0.092 (vs US$0.15 loss in 3Q 2020)

Chairman of the Board recently sold €2.7m worth of stock

Chairman of the Board recently sold €7.6m worth of stock

Second quarter 2021 earnings released: EPS US$0.064 (vs US$0.45 loss in 2Q 2020)

Tandem Diabetes Care Announces Presentations Demonstrating Positive Real-World Improvements with Control-IQ Technology Across Diverse Populations

Chairman of the Board recently sold €2.8m worth of stock

Executive VP recently sold €125k worth of stock

First quarter 2021 earnings released: US$0.081 loss per share (vs US$0.25 loss in 1Q 2020)

Tandem Diabetes Care, Inc. Revises Earnings Guidance for the Year Ending December 31, 2021

Chairman of the Board recently sold €15m worth of stock

Full year 2020 earnings released: US$0.56 loss per share (vs US$0.42 loss in FY 2019)

Revenue beats expectations

New 90-day high: €84.44

Tandem Diabetes Care, Inc. to Report Q4, 2020 Results on Feb 24, 2021

New 90-day low: €73.68

Tandem Diabetes Care, Inc. Announces Executive Changes

Chairman of the Board recently sold €2.0m worth of stock

Tandem Diabetes Care Announces Health Canada Approval of the t:slim X2 Insulin Pump with Control-IQ Advanced Hybrid Closed-Loop Technology